KO-MEN-017
HCP commentary report on Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML (NCT07007312). Trial question: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia. Aspects: Primary endpoint: Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS) (discussed, 1 verified views); Primary endpoint: Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) (discussed, 1 verified views); Primary endpoint: Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS) (no commentary found, 0 verified views); Primary endpoint: Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients (discussed, 1 verified views); Secondary endpoints (discussed, 9 verified views); Population and setting (discussed, 10 verified views); The comparison (discussed, 2 verified views); Safety and tolerability (discussed, 8 verified views); Design and conduct (discussed, 5 verified views); Early response signals and the need to demonstrate outcome improvement (discussed, 14 verified views); Dose sequencing and explanations for differentiation-syndrome differences (discussed, 6 verified views); Younger-fit triplets and a less-intensive bridge to transplant (discussed, 3 verified views). 8 sources screened, 7 cited. The sources reviewed for this edition only; not all HCPs or all public discussion.
- NCT07007312 ↗
- v1.0.0 · edition 1
- updated Oct 19, 2026
- Focused
4 findings, and what sits behind each
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 4
Frontline enthusiasm rests on early response signals, not established outcome improvement
- statements
- 10
- passages
- 11
- sources
- 4
- named voices
- 4
What the statements areViews 4Questions and uncertainty 1Clinical experience 3Comparisons 2Restated results and context 0How passages are usedSupporting a statement 12Giving context 4Recorded with the finding- Counterview: none recorded
- Limitations: 3
- Feeds the Medical Affairs question
- 1 post or article
- 3 podcasts and video
Draws on: Secondary endpoints, Design and conduct, Safety and tolerability, Primary endpoint: Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS), Primary endpoint: Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR), Population and setting, The comparison.
In the full report: the interpretation in full, all 10 statements cited to source and date, and the 4 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full KO-MEN-017 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
What evidence would justify moving from encouraging response depth to confidence in improved frontline outcomes?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 8HCP commentary sources screened
- 7sources cited by verified HCP statements
- 7found in screened sources
- 5matched to verified clinician profiles
- 7voices cited in the report
- 34verified statements, each linked to its source
- 19of them from speakers with a confirmed clinical role
- 4findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Focused) is set by the 34 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 34 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 7 | Counts free |
| Speaker attribution for cited voices | 7 | Paid |
Trial aspects
11 discussed · 1 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS) | 1 | 1 |
| Primary endpoint: Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) | 1 | 1 |
| Primary endpoint: Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS)no commentary found | 0 | 0 |
| Primary endpoint: Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients | 1 | 1 |
| Secondary endpoints | 9 | 4 |
| Population and setting | 10 | 3 |
| The comparison | 2 | 2 |
| Safety and tolerability | 8 | 4 |
| Design and conduct | 5 | 3 |
| Early response signals and the need to demonstrate outcome improvement | 14 | 4 |
| Dose sequencing and explanations for differentiation-syndrome differences | 6 | 2 |
| Younger-fit triplets and a less-intensive bridge to transplant | 3 | 1 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 5 | 4 | |
| YouTube | 3 | 3 |
max 3 / quarter
- Screened window
- Feb 11, 2025 → Oct 14, 2026
- Cited window
- Feb 11, 2025 → Oct 14, 2026
- Retrieved
- Oct 18, 2026
The trial
from ClinicalTrials.gov- Title
- Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
- Registry
- NCT07007312
- Study IDs
- KO-MEN-017 · 2025-521314-25-00
- Sponsor
- Kura Oncology, Inc.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 1,300 estimated
- Start
- 2025-09-26 actual
- Primary completion
- 2031-11 estimated
- Primary endpoint
- Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS)
- Interventions
- 6 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 16 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The discussion comes from the sources reviewed for this edition and cannot establish how common these views are among HCPs. Several posts report presentations rather than independent clinical assessments.
- No protocol or results publication for the exact KOMET-017 trial was identified. The clinical observations discussed here must not be treated as randomized KOMET-017 findings.
- The earlier response and safety accounts often omit denominators, follow-up duration or numerical rates. Zeidan's 40-patient response figures cannot be assigned to a specific frontline or relapsed/refractory cohort from the passage.
- Speaker descriptions differ in regimen detail: Zeidan named azacitidine/venetoclax, whereas Zeidner's older/unfit KOMET-017 comparison named azacitidine without venetoclax. These descriptions do not establish a clinical disagreement.
- The differentiation-syndrome comparisons concern different inhibitors, schedules and treatment settings. They do not establish a head-to-head safety advantage or a causal effect of starting treatment later.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Oct 19, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. KO-MEN-017 (NCT07007312): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 19, 2026. https://www.erudio.com/reports/ko-men-017-nct07007312
For your AI agent
The same record as JSON or Markdown, or through the Erudio MCP server
curl https://www.erudio.com/reports/ko-men-017-nct07007312.json
curl https://www.erudio.com/reports/ko-men-017-nct07007312.md
# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "ko-men-017-07007312" })release 76bdeac3e5d20ffeb8265539f86f7e7218ffed00d5e3e7d200a3901eff0b4760